Vipadenant

Vipadenant ( , ; developmental code name BIIB014 and others) is an adenosine A 2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Vipadenant ( , ; developmental code name BIIB014 and others) is an adenosine A 2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed. It is taken orally. The drug was first described in the scientific literature by 2006.

It was under development by Vernalis, Biogen, and Juno Therapeutics. Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1360264031 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.